ABSTRACT
Background: Obstructive sleep apnea syndrome (OSAS) is a common disorder associated with serious sequelae. The current gold standard diagnostic method, polysomnography, is costly and time consuming and requires patients to stay overnight at a facility. Aim: This study aimed to reveal the prevalence of OSAS in general adult population using a home sleep test (HST) during the coronavirus disease 2019 (COVID-19) pandemic. Methods: This prospective cohort study was conducted by the Department of Otolaryngology, Taipei City Hospital, Taipei, Taiwan, between January 2020 and December 2021. A total of 1372 patients aged 30-70 years completed an HST using a Type 3 portable sleep monitor (PM). The apnea-hypopnea index (AHI) was analyzed to assess the association of OSAS with age, body mass index (BMI), sex, Epworth Sleepiness Scale (ESS) and the Sleep Apnea Risk Assessment questionnaire (STOP-Bang questionnaire) rating. Results: The mean age of the patients (782 men, 57%; 590 women, 43%) was 49.24 ± 11.04 years. OSAS was detected in 954 (69.5%) patients with 399 (29.1%) mild OSAS; 246 (17.9%) moderate OSAS; and 309 (22.5%) severe OSAS. Among these, the prevalence of moderate-to-severe OSAS was 143 (10.4%) in women and 412 (30.0%) in men. The mean age was the highest (51.29 ± 11.29) in the mild OSAS group and lowest (47.08 ± 10.87) in the healthy group. OSAS severity was greater with increasing BMI, 23.39 ± 3.44 in the healthy group and 29.29 ± 5.01 in the severe OSAS group. A positive correlation was also noted between the ESS/STOP-Bang questionnaire rating and OSAS severity. Conclusion: The prevalence of OSAS in Taiwan was 69.5% in our study. It showed strong evidence that OSAS has important public health consequences and PMs are simple, fast, feasible, and cost-effective tools for OSAS screening in the home environment, especially during the COVID-19 pandemic.
ABSTRACT
OBJECTIVE: To compare the effects of botulinum toxin and steroid septal injections in treating allergic rhinitis (AR) by evaluating improvements in the rhinitis control assessment test (RCAT), visual analog scale (VAS), nasal obstruction symptom evaluation (NOSE) scores, and active anterior rhinomanometry (RMM) measurements. METHODS: This prospective, single-blinded cohort study was conducted at the Department of Otolaryngology, Taipei City Hospital between January 2017 and December 2018. Ninety-five patients were randomized to receive botulinum toxin, dexamethasone, or normal saline (group A, group B, and placebo, respectively). The main outcome measures were pretreatment subjective nasal symptoms (RCAT, VAS, and NOSE) and active anterior RMM measurements. All measurements were repeated during posttreatment 1, 2, and 3 months. RESULTS: No significant difference was observed in pretreatment questionnaire scores and RMM values between the study and placebo groups. The mean posttreatment RCAT, VAS, and NOSE scores after 1 and 2 months significantly improved in the treatment groups compared to placebo. The VAS and NOSE at posttreatment 2 months and RCAT, VAS, and NOSE at posttreatment 3 months were significantly different comparing group A to group B. All RMM parameters showed better values in group A than in group B at 1, 2, and 3 months posttreatment, with significant differences in four parameters in posttreatment 3 months. CONCLUSIONS: Botulinum toxin septal injection is a safe treatment option for AR and improves subjective nasal symptoms for 3 months. Botulinum toxin A injection tended to be more effective than steroid septal injection in terms of duration and degree.Level of Evidence: 2b, individual cohort study.
ABSTRACT
OBJECTIVES/HYPOTHESIS: To establish an ideal operative procedure of universal newborn hearing screening and to investigate whether a government-funded program increases compliance with such screening. STUDY DESIGN: Individual cohort study. METHODS: Of the 3,373 neonates born at the Taipei City Hospital during the period August 2009 to July 2010, there were 3,361 who received hearing screening with automatic auditory brainstem response (AABR) 24 to 36 hours after birth. The cost of each procedure (US $16.70) was covered by the Taipei City Health Bureau. The control group comprised 6,582 neonates born at the same hospital during the period January 2003 to December 2004, of whom 5,749 had been screened with transient-evoked otoacoustic emission (TEOAE). The cost of each procedure (US $26.70) was paid by the parents of each newborn. RESULTS: The incidence of bilateral moderate to severe hearing impairment was 0.06% (two out of 3,361) and 0.10% (six out of 5,749) in the study and the control group, respectively. The incidence of unilateral hearing impairment was 0.09% (three out of 3,361) and 0.19% (11 out of 5,749) respectively. The coverage rate of the study was significantly higher than that of the control group (99.64% vs. 87.34%, P < .001). A significant decrease of the referral rate was achieved in the study group when compared with the control group (0.95% vs. 2.82%, P < .001). The follow-up rate of the study group was significantly higher than that of the control group (100.00% vs. 40.74%, P < .001). CONCLUSIONS: The government-funded AABR program resulted in markedly better parental compliance with newborn hearing screening than the self-pay TEOAE screening program. LEVEL OF EVIDENCE: 2b.
